Profile data is unavailable for this security.
About the company
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
- Revenue in INR (TTM)71.86bn
- Net income in INR5.64bn
- Incorporated1949
- Employees16.17k
- LocationIPCA Laboratories Ltd142 AB, Kandivli Industrial EstateKandivli (West)MUMBAI 400067IndiaIND
- Phone+91 2 262105000
- Fax+91 2 228686613
- Websitehttps://www.ipca.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concord Biotech Ltd | 9.71bn | 3.05bn | 171.19bn | -- | 56.90 | -- | 47.73 | 17.64 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
Natco Pharma Ltd. | 38.28bn | 12.78bn | 182.90bn | 3.98k | 14.42 | -- | 12.61 | 4.78 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
Piramal Pharma Ltd | 77.82bn | -333.40m | 187.08bn | 6.30k | -- | -- | 26.90 | 2.40 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
Sanofi India Ltd | 28.51bn | 6.03bn | 187.78bn | 2.17k | 31.15 | 18.50 | 29.23 | 6.59 | 261.78 | 261.78 | 1,237.97 | 440.80 | 1.51 | 2.24 | 21.86 | 13,114,540.00 | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.52 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Pfizer Ltd | 22.19bn | 5.02bn | 189.54bn | 1.70k | 37.75 | -- | 32.85 | 8.54 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 196.07bn | 14.59k | 33.23 | -- | 22.36 | 3.20 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
Piramal Enterprises Ltd | 79.98bn | -20.16bn | 202.96bn | 12.22k | -- | -- | -- | 2.54 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
Laurus Labs Ltd | 49.82bn | 1.88bn | 229.55bn | 5.75k | 122.53 | -- | 40.31 | 4.61 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
Ajanta Pharma Ltd | 40.36bn | 7.36bn | 269.45bn | 7.71k | 36.74 | -- | 30.98 | 6.68 | 58.24 | 58.24 | 319.08 | -- | -- | -- | -- | 5,233,334.00 | -- | 16.13 | -- | 19.52 | 74.16 | 74.01 | 18.23 | 19.22 | -- | 100.64 | -- | 15.93 | 12.02 | 11.92 | -17.50 | 4.64 | -7.86 | -- |
Syngene International Ltd | 34.89bn | 5.10bn | 280.16bn | 6.85k | 55.13 | 6.58 | 29.93 | 8.03 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
Gland Pharma Ltd | 49.12bn | 6.59bn | 286.37bn | 4.59k | 43.49 | -- | 30.20 | 5.83 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 289.10bn | 5.10k | 57.08 | -- | 44.93 | 8.54 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 304.85bn | 15.56k | -- | -- | -- | 2.59 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
IPCA Laboratories Ltd | 71.86bn | 5.64bn | 337.03bn | 16.17k | 59.71 | -- | 36.01 | 4.69 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
Biocon Ltd | 146.13bn | 12.00bn | 349.05bn | 3.41k | 29.08 | -- | 11.58 | 2.39 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 349.93bn | 3.68k | 66.14 | -- | 58.55 | 10.57 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
Holder | Shares | % Held |
---|---|---|
DSP Asset Managers Pvt. Ltd.as of 31 Mar 2024 | 18.02m | 7.10% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 17.85m | 7.03% |
Kotak Mahindra Asset Management Co. Ltd.as of 31 Mar 2024 | 9.38m | 3.70% |
ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 6.16m | 2.43% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 5.12m | 2.02% |
HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Mar 2024 | 4.66m | 1.84% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 4.30m | 1.70% |
SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 29 Feb 2024 | 4.29m | 1.69% |
PPFAS Asset Management Private Ltd.as of 31 Mar 2024 | 3.72m | 1.47% |
Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023 | 3.27m | 1.29% |